PMID- 34012392
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210522
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 12
DP  - 2021
TI  - Calcitonin Gene-Related Peptide Monoclonal Antibody Versus Botulinum Toxin for 
      the Preventive Treatment of Chronic Migraine: Evidence From Indirect Treatment 
      Comparison.
PG  - 631204
LID - 10.3389/fphar.2021.631204 [doi]
LID - 631204
AB  - Background: The previously approved botulinum toxin and nowadays promising 
      calcitonin gene-related peptide (CGRP) monoclonal antibody have shown efficacy 
      for preventing chronic migraine (CM). However, there is no direct evidence for 
      their relative effectiveness and safety. In this study, we conducted an indirect 
      treatment comparison to compare the efficacy and safety of CGRP monoclonal 
      antibody with botulinum toxin for the preventive treatment of chronic migraine. 
      Methods: Up to August 31, 2020, we systematically searched PubMed, Embase, and 
      Cochrane Library Central Register of Controlled Trials (Central). Weighted mean 
      difference (WMD) and relative risk (RR) were used to evaluate clinical outcomes. 
      Indirect treatment comparison (ITC) software was used to conduct indirect 
      treatment comparison. Results: Ten studies were pooled with 6,325 patients in our 
      meta-analysis. Both botulinum toxin and CGRP monoclonal antibody demonstrated 
      favorable efficacy in the change of migraine days, headache days, HIT-6 score, 
      and 50% migraine responder rate compared with placebo. In indirect treatment 
      comparison, CGRP monoclonal antibody was superior to botulinum toxin in the 
      frequency of acute analgesics intake (WMD = -1.31, 95% CI: -3.394 to 0.774, p = 
      0.02113), the rate of treatment-related adverse events (AEs) (RR = 0.664, 95% CI: 
      0.469 to 0.939, p = 0.04047), and the rate of treatment-related serious adverse 
      events (RR = 0.505, 95% CI: 0.005 to 46.98, p < 0.001). Conclusion: For chronic 
      migraine patients, CGRP monoclonal antibody was slightly better than botulinum 
      toxin in terms of efficacy and safety. In the future, head-to-head trials would 
      be better to evaluate the efficacy and safety between different medications in 
      the prevention of chronic migraine.
CI  - Copyright (c) 2021 Lu, Zhang, Guo, Liu, Xu, Hu, Ni, Lu and Zhao.
FAU - Lu, Jiajie
AU  - Lu J
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Zhang, Quanquan
AU  - Zhang Q
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Guo, Xiaoning
AU  - Guo X
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Liu, Wei
AU  - Liu W
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Xu, Chunyang
AU  - Xu C
AD  - Department of Neurology, Traditional Chinese Medicine Hospital of Kunshan, 
      Kunshan, China.
FAU - Hu, Xiaowei
AU  - Hu X
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Ni, Jianqiang
AU  - Ni J
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Lu, Haifeng
AU  - Lu H
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
FAU - Zhao, Hongru
AU  - Zhao H
AD  - Department of Neurology, The First Affiliated Hospital of Soochow University, 
      Suzhou, China.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20210503
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC8126691
OTO - NOTNLM
OT  - CGRP monoclonal antibody
OT  - botulinum toxin
OT  - chronic migraine
OT  - indirect treatment comparison
OT  - meta-analysis
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/05/21 06:00
MHDA- 2021/05/21 06:01
PMCR- 2021/05/03
CRDT- 2021/05/20 06:40
PHST- 2020/11/20 00:00 [received]
PHST- 2021/04/15 00:00 [accepted]
PHST- 2021/05/20 06:40 [entrez]
PHST- 2021/05/21 06:00 [pubmed]
PHST- 2021/05/21 06:01 [medline]
PHST- 2021/05/03 00:00 [pmc-release]
AID - 631204 [pii]
AID - 10.3389/fphar.2021.631204 [doi]
PST - epublish
SO  - Front Pharmacol. 2021 May 3;12:631204. doi: 10.3389/fphar.2021.631204. 
      eCollection 2021.